Zou Ming-Hui, Kirkpatrick Stacy S, Davis Bradley J, Nelson John S, Wiles Walter G, Schlattner Uwe, Neumann Dietbert, Brownlee Michael, Freeman Michael B, Goldman Mitch H
Vascular Research Laboratory, Graduate School of Medicine, University of Tennessee, Knoxville 37920, USA.
J Biol Chem. 2004 Oct 15;279(42):43940-51. doi: 10.1074/jbc.M404421200. Epub 2004 Jul 19.
Metformin, one of the most commonly used drugs for the treatment of type II diabetes, was recently found to exert its therapeutic effects, at least in part, by activating the AMP-activated protein kinase (AMPK). However, the site of its action, as well as the mechanism to activate AMPK, remains elusive. Here we report how metformin activates AMPK. In cultured bovine aortic endothelial cells, metformin dose-dependently activated AMPK in parallel with increased detection of reactive nitrogen species (RNS). Further, either depletion of mitochondria or adenoviral overexpression of superoxide dismutases, as well as inhibition of nitric-oxide synthase, abolished the metformin-enhanced phosphorylations and activities of AMPK, implicating that activation of AMPK by metformin might be mediated by the mitochondria-derived RNS. Furthermore, administration of metformin, which increased 3-nitrotyrosine staining in hearts of C57BL6, resulted in parallel activation of AMPK in the aorta and hearts of C57BL6 mice but not in those of endothelial nitric-oxide synthase (eNOS) knockout mice in which metformin had no effect on 3-nitrotyrosine staining. Because the eNOS knockout mice expressed normal levels of AMPK-alpha that was activated by 5-aminoimidazole-4-carboxamide riboside, an AMPK agonist, these data indicate that RNS generated by metformin is required for AMPK activation in vivo. In addition, metformin significantly increased the co-immunoprecipitation of AMPK and its upstream kinase, LKB1, in C57BL6 mice administered to metformin in vivo. Using pharmacological and genetic inhibitors, we found that inhibition of either c-Src or PI3K abolished AMPK that was enhanced by metformin. We conclude that activation of AMPK by metformin might be mediated by mitochondria-derived RNS, and activation of the c-Src/PI3K pathway might generate a metabolite or other molecule inside the cell to promote AMPK activation by the LKB1 complex.
二甲双胍是治疗II型糖尿病最常用的药物之一,最近发现它至少部分通过激活AMP活化蛋白激酶(AMPK)发挥治疗作用。然而,其作用位点以及激活AMPK的机制仍不清楚。在此我们报告二甲双胍如何激活AMPK。在培养的牛主动脉内皮细胞中,二甲双胍剂量依赖性地激活AMPK,同时活性氮物质(RNS)的检测增加。此外,线粒体耗竭、超氧化物歧化酶的腺病毒过表达以及一氧化氮合酶的抑制,均消除了二甲双胍增强的AMPK磷酸化和活性,这表明二甲双胍对AMPK的激活可能由线粒体衍生的RNS介导。此外,给予二甲双胍后,C57BL6小鼠心脏中的3-硝基酪氨酸染色增加,同时其主动脉和心脏中的AMPK也被激活,但在内皮型一氧化氮合酶(eNOS)基因敲除小鼠中,二甲双胍对3-硝基酪氨酸染色没有影响,对AMPK也无激活作用。由于eNOS基因敲除小鼠表达正常水平的AMPK-α,且能被AMPK激动剂5-氨基咪唑-4-甲酰胺核苷激活,这些数据表明二甲双胍产生的RNS是体内激活AMPK所必需的。此外,在体内给予二甲双胍的C57BL6小鼠中,二甲双胍显著增加了AMPK与其上游激酶LKB1的共免疫沉淀。使用药理学和遗传学抑制剂,我们发现抑制c-Src或PI3K可消除二甲双胍增强的AMPK活性。我们得出结论,二甲双胍对AMPK的激活可能由线粒体衍生的RNS介导,c-Src/PI3K途径的激活可能在细胞内产生一种代谢物或其他分子,以促进LKB1复合物对AMPK的激活。